Redhill Biopharma (RDHL) Earnings Forecast
What Wall Street expects this business to earn, and how much analysts disagree.
Are estimates going up or down lately?
We hold no eps window in 90 days for FY26 yet. Every figure here compares one fiscal period at both ends.
No step line for this window yet. A line needs two nights of one fiscal period inside the window to join, and our record does not hold two.
| EPS | 30 days | 90 daysshown above | Since Jul 10 |
|---|---|---|---|
| FY260 analysts | Not yetour record does not hold 30 days of this period | Not yetour record does not hold 90 days of this period | Not yetour record does not reach back this far for this period |
| Dec '261 analyst | ◆ 0.0%$−352.86 to $−352.86 | ▲ +25.6%$−474.29 to $−352.86 | ▲ +25.6%$−474.29 to $−352.86 |
| Mar '271 analyst | 5 of 30 days0.0% so far | 5 of 90 days0.0% so far | ◆ 0.0%$−474.29 to $−474.29 |
Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.
If the Street is right, what does that imply for the share price?
Pick a fiscal year and a multiple and the sum runs on the numbers the Street published.
This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.
What you pay for the growth
We hold no forward multiple for Redhill Biopharma today, so there is nothing here to set against the growth the Street expects.
Is next quarter a high bar or an easy one?
Analysts expect Redhill Biopharma to lose $352.86 a share in the December quarter, the one estimate published. We hold no expected date for the next report.
For the March quarter, analysts expect a loss of $474.29 a share.
Does Redhill Biopharma usually beat or miss?
We have not been able to check a quarter yet. Our record of estimates for Redhill Biopharma begins on Jul 10, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.
We started recording estimates on Jul 10, 2026, so quarters that reported before that date cannot be checked.
Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Redhill Biopharma on Jul 10, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.
Coverage, and the gap to the filing
0 analysts publish an EPS estimate for FY26 and 1 publishes revenue. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
The full consensus, year by year
Coverage thins with distance: 1 revenue estimates for FY26, 1 for FY26.
Out-year bands widen as fewer analysts publish: 0 EPS estimates for FY26, 0 for FY26.
| Fiscal year | Revenue $B | YoY | EPS $ | YoY | EBITDA $B | Net inc. $B | Shares B | Analysts rev · EPS | Fwd P/E |
|---|---|---|---|---|---|---|---|---|---|
| FY25Filed | 0.0 | — | 0.00 | — | — | — | — | as filed | — |
| FY26E | 0.10.1 to 0.1 | ▲17592.3%a | — | n/ca | — | — | — | 1 · 0 | — |
Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over that year's filed EPS, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.
Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 0 EPS estimates for FY26, 1 for revenue. Not investment advice.

